



AF

IFW

1648


PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Aguilar Rubido et al.  
Application No. : 10/501,570  
Filed : July 13, 2004  
Title : HEPATITIS B VIRUS SURFACE ANTIGEN AS A MUCOSAL  
IMMUNOESTIMULATOR AND THE RESULTING FORMULATIONS  
  
TC/A.U. : 1648  
Examiner : Bo Peng  
Confirmation No. : 9315  
  
Docket No. : 976-18 PCT/US/RCE  
Dated : March 1, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

I hereby certify this correspondence is being deposited  
with the United States Postal Service as first class  
mail, postpaid in an envelope, addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450  
On March 1, 2007

Signature: 

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to fulfill the requirements of candor and good faith set forth in the 37 C.F.R.  
§1.56, Applicant submits herewith the following Information Disclosure Statement in  
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

**U.S. PATENTS**

<b><u>PATENTEE</u></b>	<b><u>PATENT NO.</u></b>	<b><u>ISSUE DATE</u></b>
Tabor et al.	4,547,368	October 15, 1985
Hauser et al.	5,972,346	October 26, 1999
Rose et al.	6,153,201	November 28, 2000

Applicant: Aguilar Rubido et al.  
Serial No.: 10/501,570  
Filed: July 13, 2004  
Our Docket: 976-18 PCT/US/RCE  
Page 2 of 2


### NON-PATENT PUBLICATIONS

1. McCluskie et al., "Immunization Against Hepatitis B Virus by Mucosal Administration of Antigen-Antibody Complexes," 1998, 11:245-252.
2. McCluskie et al., "Cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice," 1998, 161:4463-4466.

The above-referenced document is listed on PTO Form 1449. We have enclosed the cited non-patent document to facilitate reference to same. The Examiner is respectfully requested to consider these references in their entirety, and to indicate that he or she has done so by initialing the enclosed Patent and Trademark Office Form 1449.

This Supplemental Information Disclosure Statement is being filed within three months from the date of filing of an RCE. Therefore, applicant does not believe that any fees are due. However, if any fees are due, please charge Deposit Account No. 08-2461.

Respectfully submitted,



Edna I. Gergel, Ph.D.  
Registration No.: 50,819  
Agent for Applicant(s)

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
EIG

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
976-18 PCT/US

SERIAL NO.  
10/501,570

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT  
Rubido, et al.

CONFIRMATION NO.  
9315

(Use several sheets if necessary)

FILING DATE  
July 13, 2004

GROUP  
1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
		4,547,368	10/15/85	Tabor et al.			
		5,972,346	10/26/99	Hauser et al.			
		6,153,201	11/28/00	Rose et al.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1.	McCluskie et al., "Immunization Against Hepatitis B Virus by Mucosal Administration of Antigen-Antibody Complexes," 1998, 11:245-252.
		2.	McCluskie et al., "Cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice," 1998, 161:4463-4466.

234026\_1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.